Ratings by Roth/MKM (Kumaraguru Raja)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/29/2023 | Genenta Science S.p.A. | GNTA | New Coverage | Buy (N/A) |
5.88 (1.59) |
-72.96% | Details | |
| 5/30/2023 | Rain Oncology | RAIN | Downgrade | Neutral (Buy) |
1.10 (1.83) |
66.36% | Details | |
| 5/24/2023 | Apexigen Inc | APGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/22/2023 | Rain Therapeutics | RAIN | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2023 | Monopar Therapeutics | MNPR | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2023 | aTyr Pharma | LIFE | New Coverage | Buy (N/A) |
2.12 (18.81) |
787.26% | Details | |
| 2/27/2023 | Apexigen Inc | APGN | Downgrade | Neutral (Buy) |
1.30 (0.39) |
-70% | Details | |
| 1/31/2023 | Rain Therapeutics | RAIN | New Coverage | Buy (N/A) |
9.68 (1.83) |
-81.1% | Details | |
| 1/24/2023 | Apexigen Inc | APGN | New Coverage | Buy (N/A) |
1.83 (0.39) |
-78.69% | Details | |
| 1/5/2023 | Dare Bioscience | DARE | New Coverage | Buy (N/A) |
0.95 (2.07) |
117.89% | Details |
